Immunotherapy is less effective in non-small cell lung cancer (NSCLC) with driver mutations in epidermal growth factor receptor <i>(EGFR)</i> or anaplastic lymphoma kinase <i>(ALK)</i> and some may extrapolate this trend to other driver mutations. Here, ALK is linked to non-small cell lung carcinoma.